{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:29Z","timestamp":1793048789677,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01819-1","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:16:34Z","timestamp":1782486994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study"],"prefix":"10.1186","volume":"19","author":[{"given":"Olivier","family":"Hermine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orianne","family":"Debeaupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Heizmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Pyatilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Nojarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"de Bra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia","family":"Bumbea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Soare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"V\u00e1rkonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Belloni","family":"Fortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simge","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Michael","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Breynaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Selim","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tanasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"R\u00fcfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarita","family":"Scium\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Angelova-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baffoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"G\u00fclen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mael","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Bulai","family":"Livideanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Gourguechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dimicoli-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Mital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes N.","family":"Woltsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna N. G. Oude","family":"Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1819_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","volume":"77","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res. 2017;77:1261\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2234.","journal-title":"Cancer Res"},{"key":"1819_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325. https:\/\/doi.org\/10.1016\/S0145-2126(01)00038-8.","journal-title":"Leuk Res"},{"key":"1819_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/hematology.2022000366","volume":"2022","author":"C Akin","year":"2022","unstructured":"Akin C. How to evaluate the patient with a suspected mast cell disorder and how\/when to manage symptoms. Hematology. 2022;2022:55\u201363. https:\/\/doi.org\/10.1182\/hematology.2022000366.","journal-title":"Hematology"},{"key":"1819_CR4","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893.effective","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD, Review Article M. 2016 updated WHO classi fi cation and novel emerging treatment concepts. Blood. 2017;129:1420\u20138. https:\/\/doi.org\/10.1182\/blood-2016-09-731893.effective.","journal-title":"Blood"},{"key":"1819_CR5","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021;5:e646. https:\/\/doi.org\/10.1097\/HS9.0000000000000646.","journal-title":"Hemasphere"},{"key":"1819_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98:1286\u2013306. https:\/\/doi.org\/10.1002\/ajh.26966.","journal-title":"Am J Hematol"},{"key":"1819_CR7","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","volume":"114","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lim K-H, Lasho TL, Finke C, McClure RF, Li C-Y, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769\u201372. https:\/\/doi.org\/10.1182\/blood-2009-05-220145.","journal-title":"Blood"},{"key":"1819_CR8","doi-asserted-by":"publisher","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","volume":"9","author":"G Damaj","year":"2014","unstructured":"Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. PLoS ONE. 2014;9:e85362. https:\/\/doi.org\/10.1371\/journal.pone.0085362.","journal-title":"PLoS ONE"},{"key":"1819_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ajh.23380","volume":"88","author":"SA Wang","year":"2013","unstructured":"Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013;88:219\u201324. https:\/\/doi.org\/10.1002\/ajh.23380.","journal-title":"Am J Hematol"},{"key":"1819_CR10","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6:e638\u201349. https:\/\/doi.org\/10.1016\/S2352-3026(19)30166-8.","journal-title":"Lancet Haematol"},{"key":"1819_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/ajh.27764","volume":"100","author":"F Aperna","year":"2025","unstructured":"Aperna F, Abdelmagid MG, Kumar M, Butterfield JH, Pongdee T, Arana Yi CY, et al. Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System. Am J Hematol. 2025;100:1566\u201376. https:\/\/doi.org\/10.1002\/ajh.27764.","journal-title":"Am J Hematol"},{"key":"1819_CR12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.3390\/ijms21113987","volume":"21","author":"M Martelli","year":"2020","unstructured":"Martelli M, Monaldi C, De Santis S, Bruno S, Mancini M, Cavo M, et al. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy. Int J Mol Sci. 2020;21:3987. https:\/\/doi.org\/10.3390\/ijms21113987.","journal-title":"Int J Mol Sci"},{"key":"1819_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/thno.51872","volume":"11","author":"HC Kluin-Nelemans","year":"2021","unstructured":"Kluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, et al. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics. 2021;11:292\u2013303. https:\/\/doi.org\/10.7150\/thno.51872.","journal-title":"Theranostics"},{"key":"1819_CR14","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.19.00640","volume":"37","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, Schwaab J, \u00c1lvarez-Twose I, Shoumariyeh K, Naumann N, L\u00fcbke J, et al. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019;37:2846\u201356. https:\/\/doi.org\/10.1200\/JCO.19.00640.","journal-title":"J Clin Oncol"},{"key":"1819_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia. 2016;30:136\u201343. https:\/\/doi.org\/10.1038\/leu.2015.284.","journal-title":"Leukemia"},{"key":"1819_CR16","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136. https:\/\/doi.org\/10.1182\/blood-2013-04-496448.","journal-title":"Blood"},{"key":"1819_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bjh.17567","volume":"194","author":"N Naumann","year":"2021","unstructured":"Naumann N, L\u00fcbke J, Shomali W, Reiter L, Horny H, Jawhar M, et al. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Br J Haematol. 2021;194:344\u201354. https:\/\/doi.org\/10.1111\/bjh.17567.","journal-title":"Br J Haematol"},{"key":"1819_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny H-P, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015;29:1115\u201322. https:\/\/doi.org\/10.1038\/leu.2015.4.","journal-title":"Leukemia"},{"key":"1819_CR19","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.leukres.2007.04.008","volume":"31","author":"Y Kim","year":"2007","unstructured":"Kim Y, Weiss LM, Chen Y-Y, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res. 2007;31:1749\u201354. https:\/\/doi.org\/10.1016\/j.leukres.2007.04.008.","journal-title":"Leuk Res"},{"key":"1819_CR20","doi-asserted-by":"publisher","first-page":"102392","DOI":"10.1016\/j.bcmd.2019.102392","volume":"81","author":"A Boil\u00e8ve","year":"2020","unstructured":"Boil\u00e8ve A, Contejean A, Barreau S, Sourdeau \u00c9, Friedrich C, Kosmider O, et al. Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence? Blood Cells Mol Dis. 2020;81:102392. https:\/\/doi.org\/10.1016\/j.bcmd.2019.102392.","journal-title":"Blood Cells Mol Dis"},{"key":"1819_CR21","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.jaip.2023.02.021","volume":"11","author":"P Valent","year":"2023","unstructured":"Valent P, Hartmann K, Bonadonna P, Sperr WR, Niedoszytko M, Hermine O, et al. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives. J Allergy Clin Immunol Pract. 2023;11:1706\u201317. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.021.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1819_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaip.2018.09.024","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, et al. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019;7:81\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2018.09.024.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1819_CR23","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","volume":"32","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, et al. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia. 2018;32:1850\u20136. https:\/\/doi.org\/10.1038\/s41375-018-0121-1.","journal-title":"Leukemia"},{"key":"1819_CR24","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374:2530\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1513098.","journal-title":"N Engl J Med"},{"key":"1819_CR25","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med [Internet]. 2021;27:2192\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01539-8.","journal-title":"Nat Med [Internet]"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01819-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:00Z","timestamp":1788275220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01819-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1819"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01819-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board\/ethics committee at each participating center in the European Competence Network on Mastocytosis (ECNM) registry. All patients provided written informed consent prior to inclusion in the ECNM registry.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Olivier Hermine reports research funding from AB Science and Novartis and advisory board participation for AB Science and Blueprint Medicines. Frank Siebenhaar has received honoraria (advisory board, speaker) and\/or institutional grant\/research support from Allakos, Alys, Blueprint Medicines, Celldex, Cogent, Escient, Granular, GSK, Invea, Medison, Moxie, Noucor, Novartis, Pentabase, Pharvaris, Regeneron, Sanofi, Swixx, Telios, and Third Harmonic Bio. Polina Pyatilova reports being a speaker and\/or advisor for and\/or receiving research funding from Blueprint Medicines and Celldex, and honoraria from Granular. Marc Heizmann reports advisory board participation and honoraria from Novartis. Marek Niedoszytko reports consultancy in clinical trials for Novartis, AB Science, Telios, Blueprint Medicines, and ABM. Khalid Shoumariyeh reports advisory board participation and honoraria from Blueprint Medicines and Novartis. Friederike Wortmann reports advisory board participation and honoraria from Blueprint Medicines, Novartis, Pierre Fabre, and AbbVie. Nikolas von Bubnoff reports honoraria from Novartis and Takeda and advisory board participation for Novartis. Horia Bumbea reports advisory board participation for Novartis and Swixx. Chiara Elena reports advisory board participation and honoraria from Blueprint Medicines and Gilead. Knut Brockow reports honoraria from Blueprint Medicines, Novartis, Thermo Fisher Scientific, Advarra, AstraZeneca, BioMarin Pharmaceutical, UpToDate, ALK, HAL, and Bencard. Jens Panse reports consulting fees from Alexion, SOBI, and Omeros; honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, and SOBI; support for attending meetings and\/or travel from Alexion, Blueprint Medicines, Boehringer Ingelheim, Novartis, Omeros, Pfizer, Roche, and SOBI; participation on data safety monitoring boards or advisory boards for Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, MSD, Novartis, Omeros, Pfizer, Roche, Sanofi, and SOBI; and receipt of equipment, materials, or other services from Apellis, Blueprint Medicines, Novartis, Roche, and SOBI. Michael Doubek reports honoraria from AOP Health, AbbVie, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, and Novartis. Vito Sabato reports advisory board participation for Blueprint Medicines, Cogent, Novartis, and Telios; honoraria from Thermo Fisher Scientific; research funding from Blueprint Medicines Corporation; and is a Senior Investigator of the Flemish Research Council (FWO; Grant 1804523\u00a0N). Karin Hartmann reports lectures and consultancy for ALK, Allergopharma, BioCryst, Blueprint Medicines, Cogent, KalVista, Leo, Menarini, Novartis, Pfizer, Sanofi, Takeda, and Thermo Fisher Scientific. Axel R\u00fcfer reports advisory board participation for Blueprint Medicines. Massimo Triggiani reports advisory board participation and honoraria from Blueprint Medicines and Novartis. Paul L. A. van Daele reports lectures and consultancy for Novartis and involvement in clinical trials for Cogent Biosciences and Blueprint Medicines. Ingunn Dybedal reports honoraria for participation in scientific advisory boards from Blueprint Medicines Corporation. Cl\u00e9ment Gourguechon reports grants from Blueprint Medicines for educational activities, including travel reimbursement. Olivier Tournilhac reports travel grants and honoraria from Takeda, AbbVie, BeiGene\/BeOne, and AstraZeneca; research support from Takeda; and honoraria from Ideogen and Blueprint Medicines. Michel Arock reports research grants from Blueprint Medicines and honoraria from AB Science, Blueprint Medicines, and Thermo Fisher Scientific. Jason Gotlib reports research grants (clinical trial support) from Novartis, Blueprint Medicines, Deciphera, and Cogent Biosciences; advisory board participation and honoraria from Blueprint Medicines, Novartis, Deciphera, and Cogent Biosciences; and travel reimbursement from Novartis and Blueprint Medicines. Andreas Reiter reports honoraria from Novartis, Blueprint Medicines, Incyte, Celgene\/Bristol Myers Squibb, AOP Orphan Pharmaceuticals, GlaxoSmithKline, and AbbVie and consulting or advisory roles for Novartis, Blueprint Medicines, Incyte, Celgene\/Bristol Myers Squibb, AOP Orphan Pharmaceuticals, and AbbVie. Peter Valent reports advisory board participation and honoraria from AOP Orphan, Blueprint Medicines, Cogent, Delbert, Incyte, Novartis, PentaBase, Pfizer, and Stemline Therapeutics and research grants from AOP Orphan and Pfizer. Wolfgang R. Sperr reports honoraria from AbbVie, Astellas, Blueprint Medicines, Bristol Myers Squibb\u2013Celgene, Daiichi Sankyo, Deciphera, Incyte, Jazz Pharmaceuticals, Laboratoires Delbert, Novartis, Otsuka, Pfizer, Servier, Stemline Therapeutics, and Thermo Fisher Scientific. Julien Rossignol reports research support, honoraria for participation in scientific and clinical advisory boards, and honoraria for educational activities (including travel reimbursement) from Blueprint Medicines Corporation. All other authors declare no competing financial interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"66"}}